Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue: 2012-2020

Historic Non-Current Deffered Revenue for Agios Pharmaceuticals (AGIO) over the last 7 years, with Jun 2020 value amounting to $491,000.

  • Agios Pharmaceuticals' Non-Current Deffered Revenue fell 99.05% to $491,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $491,000, marking a year-over-year decrease of 99.05%. This contributed to the annual value of $50.6 million for FY2019, which is 15.43% down from last year.
  • According to the latest figures from Q2 2020, Agios Pharmaceuticals' Non-Current Deffered Revenue is $491,000, which was down 14.01% from $571,000 recorded in Q1 2020.
  • In the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue registered a high of $183.5 million during Q2 2016, and its lowest value of $491,000 during Q2 2020.
  • For the 3-year period, Agios Pharmaceuticals' Non-Current Deffered Revenue averaged around $48.8 million, with its median value being $53.3 million (2019).
  • Per our database at Business Quant, Agios Pharmaceuticals' Non-Current Deffered Revenue spiked by 1,074.21% in 2016 and then crashed by 99.05% in 2020.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $154.3 million in 2016, then dropped by 18.47% to $125.8 million in 2017, then plummeted by 52.46% to $59.8 million in 2018, then fell by 15.43% to $50.6 million in 2019, then slumped by 99.05% to $491,000 in 2020.
  • Its Non-Current Deffered Revenue stands at $491,000 for Q2 2020, versus $571,000 for Q1 2020 and $50.6 million for Q4 2019.